(Q37818331)

23 August 2017

1 reference

title

Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

3

Dominick J Angiolillo

1 reference

23 August 2017

author name string

Salvatore D Tomasello

series ordinal

1

1 reference

23 August 2017

Antonio Tello-Montoliu

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

13 December 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

119-133

1 reference

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in My

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Clinical end points in coronary stent trials: a case for standardized definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.538381

10.1517/13543784.2010.538381

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference